Based at the Charles River Laboratories High Peak site, UK, Aisha is responsible for growing the Retrogenix Cell Microarray Technology in the Asia-Pacific region. She joined Charles River through the acquisition of Retrogenix Ltd. Previously, Aisha supported lead generation and client outreach activities in Asia-Pacific and Europe, helping to bring the Retrogenix Cell Microarray to new markets.
Aisha has a Master of Science degree in Biological Sciences from The University of Manchester and an undergraduate degree in Biochemistry. Her previous experiences include working as a scientist at the Alderley Park Lighthouse Lab to help tackle Covid-19. Her laboratory experience includes working in a class 3 containment environment handling live viruses with experience in qPCR and RTPCR. She also has extensive experience in Microbiology and tissue culture.
Antonio Lee serves as the CEO and Managing Director at MEDIPOST America Inc., a wholly-owned U.S. subsidiary of MEDIPOST. He is also the Global Head of business development at Medipost , S.Korea.Prior to this he was the Chairman, Board of DirectorsatShandong Orlife Pharmaceutical Co.,China and is also Chairman, Board of Directors at EVASTEM Co., Ltd. Tokyo, Japan
Since 2011, Dr. Lee has been involved in the global commercialization and clinical development strategy, regulatory affairs and marketing of human Umbilical Cord Blood (hUCB)-derived Stem Cell technology and products developed by MEDIPOST, including the World’s First regulatory-approved allogeneic stem cell product - CARTISTEM®, for the treatment of knee Osteoarthritis (OA).
He is a Doctor of Philosophy, University of Otago, Dunedin, New Zealand Developmental Biology & Embryology ; A Master of Science,University of Otago, Dunedin, New Zealand Clinical Anatomy and Bachelor of Science with Honours, University of Otago, Dunedin, New Zealand Anatomy & Physiology
He has published several articles in world renowed journals on various topics around stemcells and regenerative medicine.
Dr. Bin Xiang, a biologist by training, has solid research experience in disease biology, intestine biology, genome editing, AAV and bacterial vector gene therapy. Dr. Xiang founded CommBio Therapeutics Co., Ltd. in 2019 and devote to develop novel medicine by focusing on intestine biology and bacterial delivery system. Currently, Dr. Xiang is the CEO of CommBio, and the College Advisor at ShanghaiTech University.
Dr. Xiang obtained Ph.D in neurobiology from Fudan University Shanghai Medical School in 2001, followed by postdoctoral training in cancer biology at Cold Spring Harbor Laboratory and research fellow in cancer translational research at Vanderbilt University Medical Center.
In 2008, Dr. Xiang switched career to drug discovery and joined AstraZeneca Innovation Center China working on oncology translational medicine. In 2011, Dr. Xiang joined China Novartis Institutes for Biomedical Research. At Novartis, Dr. Xiang was the project team leader having directed both small molecular drug and AAV gene therapy in oncology and metabolic disease. In addition, Dr. Xiang led an innovation group exploring novel disease mechanism from intestine biology and developing new class of drug approaches including genome editing and gene therapy.
Dr. Bose Kalampanayil is Chief Technology Officer at Neurophth since 2019.Dr. Kalampanayil has over 20 years of experience in the biopharmaceutical industry, including CMC experience in cell and gene therapy and vaccine manufacturing. Most recent cell/gene therapy experience and consultations include, GMP Plasmid Productions, GMP Upstream and Downstream Productions for various AAVs (AAV2, 5, 6, 8 & 9). Served as a “Subject Matter Expert” in process engineering, process development and CDMO selection processes for GMP Manufacturing. Held management positions in several biotechnology companies and CDMOs in USA, including Vigene Biosciences, Therabron Therapeutics, AERAS, Iomai (Intercell) and Charles River Laboratories. Dr. Kalampanayil has a PhD in Biochemistry from University of Maryland and hold American Board certification in Clinical Chemistry.
Dr. Kuan co-founded ARCE Therapeutics in 2020 and is the President and CEO. He leads ARCE from discovery toward clinical trials in developing next generation cell therapies such as CAR-engineered cells, for cancer treatment, including liquid and solid tumors, and immunological disorder diseases. He has more than 30 years of experience in research and development of therapeutic antibodies, protein fusions, and cellular gene therapy for the treatment of cancer, autoimmune, neurodegenerative and infectious diseases, including Duke University Medical Center and Development Center for Biotechnology. His areas of expertise include antibody engineering, recombinant immunotoxins, bispecific antibodies, and CAR-T/NK cell therapies for cancer treatment. Dr. Kuan obtained his Ph.D. degree from Purdue University in the USA; and his B.S. degree from National Taiwan University in Taiwan.
Cheng-Yi Jerry Kuo
- Degree in Biochemistry and Genetics from University of Nottingham, UK
- PhD in Biochemistry from University of Bristol, UK
- Based in Singapore for the past 11 years
- Previous experience as both a global application specialist , before transitioning to head up Asia Pacific region (Molecular Devices (a Danaher company) and Horizon Discovery (a Perkin Elmer company)
- Currently VP of Asia Pacific for Gamma Biosciences
- Expertise in cell line development, high content imaging, downstream bioprocessing and cell and gene therapy
David has 15+ years of experience in the pharmaceutical industry spanning the drug discovery and development process. He has held roles as scientist and consultant in biotech startups, consulting, contract research at AMRI Global and GMP manufacturing at GSK. Most recently, he worked on process development and manufacturing strategies to supply material for preclinical and first-in-human studies, including cell and gene therapies. He holds a PhD in Organic Chemistry from the Australian National University and a Bachelor of Technology (Hons) in Chemical Technology from Massey University, New Zealand.
Dr Domenica Martorana is an R&D scientist working on gene regulation and digital PCR assay product development at QIAGEN, Hilden, Germany. She studied Molecular and Cellular Biology at the Georg-August University in Göttingen (Germany), where she received her PhD in 2019. Her PhD research focused on the transcriptional regulation of the unfolded protein response in both fungi and higher eukaryotes. Along the way she has gathered extensive experience in gene editing and gene regulation in different international projects. Since joining QIAGEN in 2019, Dr Martorana has been involved in the development of CRISPR- and functional genomics-related products as well as in dPCR application products with focus on Cell and Gene therapy.
Dr. Dong Wei joined EdiGene as CEO in 2018, a biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer.
Prior to EdiGene, Dr. Wei had over 20 years of experience in innovative drug development and management, including leading over 10 global clinical-stage programs in multiple therapeutic areas at BioMarin, Elan, Johnson & Johnson and Shire, advising healthcare and life science clients on strategic and operational issues at Deloitte Consulting, as well as conducting drug discovery and technology development at Chiron and Applied Biosystems.
He holds BS in Genetics from Peking University, Ph.D. in Microbiology from Michigan State University and MBA from the Wharton School of University of Pennsylvania.
Dr. Edmund Ang, a Senior Technical Expert and joined Merck’s BioReliance Biosafety Testing in 2017. Dr. Ang provides technical support on CMC testing of biotherapeutics to biopharma developers and manufacturers in Asia Pacific. He has more than 20 years of experience in life science industry with R&D experience in cancer drug and biomarker discovery at Eli Lily and Ionis Pharmaceuticals, as well as commercial technical experience in cellular analysis and bioproduction with Roche Diagnostics, Life Technologies/Thermo Fisher Scientific.Dr. Ang obtained his Ph.D. in Cell Biology from the University of Edinburgh and conducted his postdoctoral research on cell signalling at Stanford University and National Cancer Centre, Singapore.
Assistant Professor Francesca Lim is a Consultant Haematologist at Singapore General Hospital (SGH), Deputy Head, Principal Lead (Education) and Lead (Blood Cancers) at the SingHealth Duke-NUS Cell Therapy Centre and Assistant Medical Director at the Cell Therapy Facility, Health Science Authority.
She spent two years training at the MD Anderson Cancer Center in CAR T-cell therapy, particularly in CAR-NK cell therapy. She has been instrumental in supporting and coordinating the Cell Therapy Programme at the SGH Department of Haematology, both at the clinical and research levels.
Dr. Harry Murti is a Research Manager at Stem Cell and Cancer Institute (SCI) and also involved in Process Development at ReGeniC (PT. Bifarma Adiluhung: The First Registered & GMP certified Stem Cell Manufacturingin Indonesia). His main research interest is in vitro and in vivo (pre-clinical) as well as clinical studies of stem-cell-based treatment in degenerative diseases. He is also a member of Association of Indonesia’s Stem Cells.
Hendrick Loei is the APAC sales manager at Halo Labs. He is responsible for commercial operations of Halo Labs in the Asia Pacific region. Prior to Halo Labs, Hendrick has held various technical and commercial roles at Fortebio (now a part of Sartorius), Merck Bioreliance and Berkeley Lights. A molecular biologist by training, Hendrick obtained his BSc and MSc in biochemistry from the National University of Singapore. His other technical experience included proteomics, biomarker discovery, biomolecular interaction analysis and biosafety testing.
Ivan D Horak
Dr. Horak brings more than 20 years of experience in the global pharmaceutical industry, predominantly focused on oncology drug development, and is a board-certified medical oncologist. Prior to joining Tessa, Dr. Horak was Head of Global R&D and Chief Scientific and Medical Officer at Symphogen, a clinical-stage antibody company, and President of R&D at Enzon Pharmaceuticals, Inc. Dr. Horak has also held a number of senior research leadership positions in various pharmaceutical companies as well as at the National Cancer Institute (NCI). During his career, Dr. Horak has advanced multiple oncology treatments into the clinic, and has successfully led a number of FDA new drug applications.
Dr Jeonghoon Han graduated from University of Medicine & Dentistry in New Jersey with Ph.D. degree with his research interest in apoptosis, especially in cancer field. In 1999, he was a research fellow in Dana Farber Cancer Institute in Harvard Medical School for two years. He changed his career from oncology research to medical affairs and marketing in multi-national pharmaceutical companies (Eli Lilly, AstraZenca, BMS, Boehringer Ingelheim, Mundipharma, Teva, Amgen).
With the seven years’ experience of basic and translational researchs in academy and the eighteen years’ experiences of medical affairs and marketing in seven multinational pharmaceutical companies, he established the strong foundation of building competitive R&D and medical affairs’ strategies for developing differentiated pipelines in terms of global regulatory approval and commercial success.
In 2018, he joined Eutilex (Korean BioTech company) and generated & implemented pipeline development strategies and achieved IPO Success in South Korea (Dec 24th, 2018). Currently he is focusing on conducting EBViNT clinical trial in order to generate strong efficacy data and licensing out Eutilex key pipelines as a Chief Business Officer.
He awarded Global Brand Award of Iressa in 2005, Excellent Achievement in Oncology Business in Eli Lilly in 2002, Damon Runyon-Walter Winchell Fellowship Award in 1999~2000, Gallo Award for Outstanding Cancer Research presented by The Cancer Institute of New Jersey in 1997 and Excellence in Research from the Cancer Institute of New Jersey in 1996.
Dr. Juliana Gutierrez is Healthcare Scientific Affairs manager at bioMérieux Industrial Microbiology Unit Asia Pacific and is based in Singapore. Juliana provides scientific expertise and support to the bioMérieux Healthcare Business across Asia. She has been working in Asia for more than 6 years in different capacities, initially in Japan as Scientific Affairs and more recently in Singapore as Regional Marketing.
Dr. Ke Zhang is the Chief Scientific Officer and a member of the Board of Directors of SCG Cell Therapy. Before joining SCG, Dr. Zhang acted as the principal project leader at Janssen/Johnson & Johnson China R&D for a series of antiviral projects against chronic hepatitis B and HBV-related hepatocellular carcinoma from discovery into clinical development. Dr. Zhang earned his Ph.D. in Molecular Medicine at the Faculty of Medicine, Technical University of Munich and received his postdoctoral training at the Institute of Medical Virology, Helmholtz Munich - German Research Center for Environmental Health.
Keiichi Fukuda is pioneer of the cardiac regeneration field and has been at its cutting edge for the past 20 years. He has made several contributions to both the fundamental biology of the stem cells and how to regenerate cardiomyocytes and to transplant them into the in vivo heart. He first reported that bone marrow mesenchymal stem cells can be induced to differentiate into cardiomyocytes in vitro. He first developed a method to generate iPS cells from peripheral circulating T lymphocytes using Sendai virus containing Yamanaka factors. He found several factors such as noggin, Wnt and G-CSF, and applied them to induce cardiomyocytes. He also developed novel method to purify the cardiomyocytes by the difference of metabolic energy pathway. He became Chief Professor of the Department of Cardiology in Keio University, and published more than 600 top-ranked papers including Nature- and Cell-sister journals. He served as an associate editor of JMCC and JCF, and a consulting editor of Circulation Research. He also worked as editorial board members for more than 10 international journals. He had established bio-venture company “Heartseed Inc.” in 2015 and became CEO. He is now planning to examine the clinical trial for transplantation of human iPS-derived regenerated cardiomyocytes to the patients with congestive heart failure in 2022.
Dr. Lu-En Wai has 15 years of experience in immunology research, in the fields of transplantation, cancer and Hepatitis B Virus (HBV) immunopathogenesis. She obtained her Ph.D. in Immunology from Stanford University focusing on immune cell interactions in liver transplantation and cancer. At the Singapore Immunology Network, she investigated the role of the immune microenvironment in controlling tumour metastases. Subsequently, she joined Dr. Antonio Bertoletti’s lab at Duke-NUS to study HBV immunopathogenesis in a humanized mouse model in collaboration with the Institute of Molecular and Cell Biology. In 2017, Dr. Wai joined Lion TCR, a Singapore biotech start-up co-founded by Dr. Bertoletti, focused on using T cell receptor (TCR) T cell immunotherapy to treat viral infections and viral-related cancers, particularly Asian-centric diseases like HBV-related liver cancer. As Director of Research and Development at Lion TCR, Dr. Wai oversees the discovery and development of the TCR library, companion assay development, and pre-clinical R&D of new pipeline products including enhanced TCR-T cells and allogeneic TCR technologies in collaboration with academic and industry partners. She is passionate about developing new technologies in immunotherapy and diagnostics for the treatment of diseases.
Rain is the Upstream Technical Application Expert for SEATW & Oceania region in Merck Life Sciences based out of Singapore. She provides technical application consultation for products & technologies applicable for upstream processing in the biopharmaceutical industry - not limited to CHO-based biotherapeutics but also include vaccines and cell & gene therapies. Driven by innovative and curiosity, she takes pride in providing the best possible solutions and perspectives in problem solving.
Rain began her career as R&D Scientist in environmental industry. Prior to Merck, sha has gained experience in Product Management role with Thermo Fisher Singapore, supporting the life sciences industry from research to clinical applications. She has more than 7 years of experience in the biopharmaceutical industry and developed partnerships with customers from multinational corporation, CDMO and emerging biotechs.
Dr. Rajarshi Pal has a unique experience of 15+ years across industry and academia. In 2014, he completed an Indo-US fellowship wit Dr. Kapil Bharti, Senior Investigator, National Eye Institute-NIH, Bethesda, MD, USA. He was among the first in employing human stem cells and their progenies like heart and liver for in vitro drug testing. On the basic side, he made substantial advancements in understanding human disease biology by using stem cell-derived spheroids and organoid models. On the translational research side, he contributed significantly towards developing novel cell-based replacement therapies for incurable disorders using specialized tissue specific cell types. His group has created normal and patient-specific human induced pluripotent stem cell (hiPSC) lines and have established robust protocols to differentiate them into alveolar and airway epithelial cells, retinal pigment epithelium and photoreceptors for pre-clinical and clinical studies. Dr. Pal has published over 50 papers in peer-reviewed journals of high international repute; has 6 patents to his credit and has contributed for 8 book/protocol chapters.
Ravin Mehta is instrumental in strengthening the foot-print of Sartorius’s offerings in the Advanced Therapies Domain within APAC. He along with his team enables APAC based clients to discover, develop and manufacture the immune or stem cell based therapies utilizing Sartorius portfolio of products across the spectrum. Prior to joining Sartorius, Ravin has spent over 10 years in biosimilar product development, where he gained significant experience in cGMP manufacturing as an cell line and upstream bioprocess scientist. He also attained skills in management by supporting biologics development services for WuXi AppTec, one of Asia's largest biopharma CROs. His technical expertise is underpinned by a post graduate degree in Biotechnology and an MBA in International Marketing. His current role at Sartorius focuses on establishing the technical & commercial foot print for Sartorius’s Advanced Therapies offerings as a first step in imparting Total Solutions to the Asian Biopharmaceutical Fraternity enabling them to deliver safe and affordable therapies to patients faster.
Revathy has completed her MS in Organic chemistry from Wayne State University, Detroit, MI USA. After several years as a bench chemist in Bristol Myers-Squibb, Versicor & AstraZeneca, she moved into an operational role managing EHS/Stores/procurement at AstraZeneca in Bangalore.
After a 4-year stint as Head of EHS at the Biocon BMS R&D Centre she took a break to explore other perspectives. In 2017 she re-joined Syngene as Head of Health and Safety post which she accepted this opportunity to head up Facilities and Operations at Immuneel Therapeutics.
This exciting opportunity allowed her to explore and learn multiple functions like Admin, Procurement, Supply chain and Logistics and IT administration while continuing to handle the core functions of Infrastructure and operations of the GMP labs and the entire Immuneel facility.
The entire Immuneel facility has been designed and built with her inputs and under her supervision.
Founder, Chairman and CEO， Neukio Biotherapeutics
VP & CTO, Fosun Pharma
Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years
COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies
Head of Operations, GSK R&D Center in China
Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China
Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA
Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA
Richard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.
Roberto Nitsch graduated in Medical Biotechnology from the University of Naples (Italy) where he also obtained his PhD in Molecular Genetics. He later moved to Vienna where he focused on mouse genetics and cancer biology, and lately recessive genetics. He then shifted his research topic to genome engineering with CRISPR/Cas9 and joined AstraZeneca in 2014 where he was responsible of the CRISPR mouse models for drug discovery and oncology. Since 2017, he is Associate Director in the the Director of the Gene Therapy at AstraZeneca, and he is working towards the generation of safer CRISPR medicines.
Ryuichi Morishita, M.D., Ph.D., graduated Osaka University Medical School in 1987, and received Ph. D. from Osaka University in 1991. After following postdoctoral Fellow at Stanford University School of Medicine, he served as an Assistant Professor, Department of Geriatric Medicine, Osaka University Medical School from 1994 to 1998. Then, from 1998 to 2003, he was Associate Professor, Division of Gene Therapy Science, Osaka University Medical School. Then, he became Professor & Chairman of Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University Medical School from 2003 to present.
Professor Morishita received over 20 awards from various academic societies including Harry Goldbratt Award in Council of High Blood Pressure, American Heart Association, Award in Japanese of Japan Medical Society, Sato Award in 27th annual meeting of the Japanese Circulation Society and Invitrogen-Nature-Biotechnology Award.
Professor Morishita is currently on the editorial board of over 30 scientific journals including Open Medicine Journal (Editor-in-Chief), Gene Therapy, ATVB, Circulation and Hypertension. He has published over 400 original articles and review papers, primarily on gene therapy and molecular biology in cardiovascular disease. In addition, Professor Morishita is a Board Chairman of Japanese Society of Gene & Cell Therapy. He is currently Strategic Advisor of Headquarter for HealthCare Strategy (Chief is Shizo Abe, Prime Minister of Japan). He is also Special Advisor of Osaka Prefecture and Osaka City.
He is the Founder & Medical Advisor, AnGes Inc. and also Founder & Medical Advisor at FunPep Inc.
Dr Qlintang joined KALBE in 1999 and now leads in three of Kalbe's subsidiaries, namely Stem Cell and Cancer Institute, is a Kalbe’s Research, PharmaMetric Labs, is a CRO company and Bifarma Adiluhung, is a Stem Cell Manufacture with GMP certificate.
He is a reviewer member in Ministry of Research and Technology/National Research and Innovation Agency (Indonesia)since2019 and also member in Consortium of tissue engineering and stem cells, Ministry of Health since 2014, board member in Association of Indonesia Tissue Engineering and Cell Therapy since 2016 and member of Association of Indonesia’s Stem Cells since 2020.
Dr. Sareina Wu is a pioneer in virus-free gene therapy.She founded GenomeFrontier Therapeutics Inc. (GF), a startup company, in July 2018 and currently serves as Chief Executive Officer and Chief Scientific Officer.GF is an innovation-driven therapeutic company focusing on the development of Gene and cell therapies. Striving to reach the pinnacle in the field of gene therapy, Dr. Wu contributed four crucial proprietary virus-free gene and cell engineering platforms that the company have leveraged to successfully create a robust cell engineering Quantum Engine™ that has the potential to cure a wide-range of diseases including cancers.
Before founding of GF, as a pioneer in developing a virus-free based genetic platform for human gene therapy, Dr. Wu founded Celgenomics, LLC in Georgia, USA. She also served as Assistant Research Professor at Chang Gung University and was a Faculty member at the Medical College of Georgia. Her work in the field of piggyBac is recognized internationally. Currently, Dr. Wu is focusing on immune-oncology and is utilizing the piggyBac-based Quantum Engine™ to develop a number of CAR-T and TCR-T genetic reprograming cell products for cancer treatments.
Saw Khay Yong
Dr. Khay Yong Saw is a Consultant Orthopaedic Surgeon and founder of the Kuala Lumpur Sports Medicine Centre. He graduated from Liverpool University Medical School in 1984, obtained his FRCS in Edinburgh in 1989 and went on to his chosen field which was Orthopaedic Surgery. In 1993, he completed his Masters in Orthopaedic Surgery (MCh Orth) at the Liverpool University Medical School, UK. His specialization in orthopaedic sports medicine includes knee joint arthroscopic surgery with application of stem cells for chondrogenesis together with bone and soft tissue regeneration. In Year 2005, he started his research work in Articular Cartilage Regeneration with the use of stem cells. He has received numerous awards in the field of regenerative medicine for knee cartilage injuries. Other than his patents and publications in the field of peripheral blood stem cells for musculoskeletal regeneration, he regularly shares his experience and knowledge at local and international conferences and events as an invited speaker. He has also organized and conducted many arthroscopic courses, some of which included live surgery.
Seong-Wook Lee, Ph.D.
Dr. Lee found Rznomics Inc., RNA-based biopharmaceutical company, in 2017 and has served as President and CEO. Dr. Lee is also currently a full Professor at Dankook University in Korea since 1997. He received the B.Sc. and M.Sc. degrees in Dept. of Microbiology from Seoul National University and obtained Ph.D. degree in Dept. of Molecular Biology at Cornell University. He was working as a graduate research assistant in Memorial Sloan-Kettering Cancer Center and as a research associate and a visiting scholar in Duke University Medical Center. His areas of expertise include development of RNAs as gene therapeutics as well as diagnostics. Especially, he has focused on developing RNAs for the treatment and prevention of diverse intractable diseases including genetic, infectious, degenerative, and malignant diseases. He serves now as an editorial board member of renowned international journals especially in the field of nucleic acid gene therapy including ‘Nucleic Acid Therapeutics’ and ‘Molecular Therapy-Nucleic Acid’. He served as President of ‘Korean Society of Gene and Cell Therapy’.
Shashwati Basak Phd
Dr Shashwati Basak has a PhD in Molecular and Cell Biology and two postdoctoral fellowships in gene expression, regulation and cancer signalling pathways from Salk Institute for Biological Sciences and Stanford University. She has 20+ years of scientific leadership experience in translational research, clinical biomarkers, analytical assays and technology platforms. She has worked in several Biotech / Biopharma companies including Biocon Bristol Myers-Squibb R & D center, Aurigene Discovery Technologies and Immuneel Therapeutics Ltd and held positions of increasing responsibilities, in varied roles. Currently, as an Independent Consultant, her focus is on various aspects of drug development, especially in Cell and Gene Therapy, including Quality and Compliance in CGT.
Dr. Sharon Du serves as the Director of Business Development in GenScript ProBio. She is in charge of CDMO business development and client relationship maintenance for APAC and India.
Sharon has 7 years' industry experience and held positions in Terumo BCT and Miltenyi Biotec where she worked closely with clinical and research clients, including hospitals involved in CTGTP. Sharon obtained her Ph.D degree from National University of Singapore where She focused on immuno-oncology research, particularly in CAR-T and iPSC. She has co-authored 9 peer-reviewed publications and possesses industry expertise in cell culture, flow cytometry and automated cellular therapy product manufacture.
Active in the cellular therapy and CDMO filed, her passion is to bring cutting edge technologies into clinical to benefit more patients through innovative therapies.
Steve has 30+ years of global experience in the Biotech industry and 21 of those years has been on human adult and pluripotent stem cell bioprocessing. He has developed a variety of patent families for the manufacture of mesenchymal stem cells, reprogrammed human induced pluripotent stem cells and created neural cells, cardiomyocytes, blood cells, cartilage, bone and retinal pigment epithelial cells at bioreactor scale using a range of microcarrier technologies. He has developed biodegradable microcarriers for cell manufacturing and microfluidics devices for microcarrier, cell and debris separation. Most recently, a novel method of directed differentiation using CRISPR technology that will accelerate therapeutic applications of stem cells was patented. He also created a machine learning model for predicting cartilage repair with MSC.
Steve has received research funding grants totalling over SGD 25 million. He has 43 Patents, granted and pending, over 135 scientific publications, written 2 books and created 3 companies.
Steven Thomas is the global head of Twist Biopharma Business Development. Steven is trained as a molecular biologist and has extensive experience in both nonprofit and commercial settings. He is proficient in synthetic biology design and fabrication and has expertise in the use of synthetic libraries for antibody discovery and engineering.
Tan Wee Kiat
TAN Wee Kiat, Ph.D., is the Chief Operating Officer in CytoMed Therapeutics Pte Ltd; an A*STAR spin-off, Singapore. CytoMed Therapeutics possess a R&D laboratory in Singapore and a PIC/S cGMP manufacturing facility in Johor, Malaysia to support the manufacturing needs of the company. Prior to joining CytoMed Therapeutics, he was involved in another biotechnology company and was responsible for process mapping and development for cell based immunotherapy. He received his Ph.D from National University of Singapore (NUS) and his research focused on cell-based cancer immunotherapeutics using a wide variety of immune cells including Natural Killer cells, gamma delta (γδ) T cells, dendritic cells and CAR
γδ T cells. Also experienced with using Baculovirus mediated gene delivery and human induced pluripotent stem cell (hiPSC) reprogramming and differentiation, he is now dedicated to driving CytoMed Therapeutics’ platform technologies into clinical applications and therapeutic products for solid and haematological malignancies.
Into its 7th edition, Cell and Gene Therapy World Asia has firmly established itself as Asia's THE cell and gene therapy gathering for new partnerships, ideas and knowledge. We are proud to continue the meeting platform where Asia's growing cell and gene therapy industry is at the forefront, receiving more and more global attention on its fast advancement in new therapies, R&D and biomanufacturing.
Since 2017, Cell & Gene Therapy World Asia has witnessed huge success in bringing over 300 industry pioneers from both cell & gene therapy industry. With the mission to facilitate the research & development and manufacturing of high quality cell & gene therapy treatments and regenerative medicines in Asia, Cell & Gene Therapy World Asia is going to continue its legacy.
In addition, this year, speakers will be exploring innovations in cell & gene therapy in Asia region, best practices on cell & gene therapy manufacturing and process development, scale out strategies, cost optimization, next generation on CART, advances in CART manufacturing, preparation for commercialization, regulation case studies and more.
Join the conference to interact with key and upcoming entities from Asia cell & gene therapy companies including BeiGene, Gracell Biotechnologies, Fosun Kite Biotechnology, Tessa Therapeutics, CARSgen, Senlang Bio, Kangstem Biotech, Medigen Biotechnology Corp, Shangai UniCAR Therapy among others.
Catch the latest cell & gene therapy development in Asia. From current best R&D practices to advancing towards manufacturing and commercialization from most-exclusive case studies to industry's key needs. All this and more under 1 roof.
Innovations in Cell & Gene Therapy in APAC Region
Advances in CAR-T/NK Cell Manufacturing
Next Generation Gene Editing Technologies
Cell Therapy Manufacturing and Process Development
Gene Therapy Process Development & Optimization Strategy
Clinical Case Studies in Gene Therapy
Next Generation CAR-T Cell Therapies - Case Studies from Asia
Innovative Approaches to AAV Vector Manufacturing
Analytical & Characterization Strategies for Viral Vectors
Preparing For Commercialization And Launch Strategy Success
Supply Chain Management And Cryo Techniques
Regulations & Commercialisation Case Studies
Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions support our customers in producing drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.
GenScript is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
For more information, visit www.genscript.com
Principal Contact Name: Cassie Yap/ Boon Hwa Tay
Email Address: [email protected] / [email protected]
Position: Marketing Supervisor / Marketing Specialist
Merck, a leading science and technology company, operates across life science, healthcare and
electronics. To the life science industry, we provide solutions and services for research,
biotechnology development and production, and pharmaceutical drug therapy development
The Millipore® portfolio of Merck offers an ecosystem of industry-leading products and
services, spanning preparation, separation, filtration, and monitoring, as well as clinical and
commercial biomanufacturing CTDMO services - all of which are deeply rooted in quality,
reliability and time-tested processes. The SAFC® portfolio of Merck offers customized and
ready-to-use raw material solutions, backed by deep regulatory expertise. Our proven products,
expert services and regulatory and application expertise are a strong foundation you can rely on
to consistently perform at the highest level.
For more information, please visit https://www.merckmillipore.com and
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Further information can be found at http://www.qiagen.com.
MasterControl Inc. is the leading provider of cloud-based quality and compliance software for life sciences and other regulated industries. Our mission is the same as that of our customers – to bring life-changing products to more people sooner.
You can use the MasterControl Product Lifecycle Excellence™ platform to digitize, automate and connect quality and compliance processes at every step – from concept to commercialization. Join over 1,000 companies worldwide that rely on MasterControl solutions to achieve new levels of operational excellence across product development, clinical trials, regulatory affairs, quality management, supply chain, manufacturing and postmarket surveillance.
Learn more at www.mastercontrol.com
Halo Labs knows aggregates and particles. The Aura can count and characterize subvisible particles and tell you if they are aggregated drug product, excipients, or external contaminants. A simple, plate-based approach enables low-volume, high-throughput, fully automated particle imaging and analysis at any stage from developability assessment through quality control.”
Pharmaceutical industries have stringent regulations when it comes to quality and safety.
In order for businesses to remain competitive in this industry, they need accurate and
fast microbial contamination detection solutions that are adaptable and cost-effective.
bioMérieux helps the pharmaceutical and healthcare industries unlock greater value from
their organizations through a complete line of diagnostic solutions that enable more rapid,
consistent results. Reliable and quick results improve safety, enhancing your brand
protection, and maintenance of safer pharmaceutical products. bioMérieux solutions
protect your product quality.
Gamma Biosciences is a leading life sciences company providing products and services to support the development and manufacturing of advanced biologic therapies. Our operating companies are committed to advancing the science and art of bioprocessing by delivering market-ready innovation and expertise that helps our customers, mainly biopharmaceutical companies and contract development and manufacturing companies, safely bring therapies to patients more quickly and efficiently. Gamma is a global company with offices and major manufacturing facilities in North America, the U.K. and Belgium.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.
The drug research and development process is highly complex, yet essential for delivering safe and effective therapies to patients. Even though the process is well defined, drug development programs are fundamentally different for each product.
Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help customers (or the industry) optimize process economics while meeting strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia. Learn more at www.polyplus-transfection.com.
Azenta Life Sciences provides unrivalled sample exploration and management solutions to help our customers accelerate discovery, development, and delivery to bring impactful breakthroughs and therapies to market faster. We are the global leader in automated compound management for drug discovery, biological storage and particularly in protecting sample integrity with our automation cryogenic storage capability that combines the best in sample security, data management and inventory control.
As a global leader in R&D genomics, we support scientists in their in vivo gene therapy research with Azenta’s unique AAV-ITR sequencing, transgene synthesis and plasmid preparation. Azenta’s ground-breaking AAV services also include sequence verification and correction of inverted terminal repeat (ITR) regions, which are crucial for rAAV packaging production.Meet us at IMAPAC’s 6th Edition Cell & Gene Therapy World Asia 2022 and find out more about our automated compound management as well as our end-to-end DNA AAV solutions.
Comecer, an ATS company, is a developer and manufacturer of high-tech systems in the field of Aseptic Processing and Containment for Pharmaceutical Industries. It designs and manufactures customized isolation technology equipment for pharmaceutical, biotech and chemical applications.
Its containment solutions range from isolators that handle highly active principles or excipients to multi-stage isolators for chemical synthesis or laboratory operations. Its asepsis offerings include isolators designed for sterility tests and formulation of sterile drugs, isolators or RABs integrated into filling lines, and dedicated solutions for Regenerative Medicine applications.
Comecer products are known and used in hospitals, universities, research centers, pharmaceutical companies, cell factories and large industrial groups worldwide.
For over 40 years, QuickSTAT has been providing the leading pharma and biotech companies 24/7/365 global life science logistics solutions from R&D, clinical trials through to commercialization.
Our logistics experts provide time-and temperature-sensitive transport of clinical research samples, cell and gene therapies, investigational drugs, clinical trial supplies and vaccines, to bring new drugs to market. Strict chain of custody, chain of identity and GDP protocols ensure product integrity and patient safety for all clinical and commercial personalized medicines QuickSTAT transports. Consultation and procurement of proper packaging—from controlled room temperature to cryofrozen. Next gen IT logistics software provided for managing your clinical supply chain.
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.
ACROBiosystems' catalog includes a comprehensive list of disease-associated biomarkers and drug targets from humans to other common species. All of our products are produced with high quality and batch-to-batch consistency to satisfy the rigorous standards of pharmaceutical research and development.
As ACROBiosystems' only distributor in India, Allianz BioInnovation is an ISO 9001: 2015 Certified Biotech company offering innovative Life Science Research tools from renowned companies across the world who are world leaders in their respective fields. The company has gained recognition, success and growth to its present position of a leading distributor as a result of our focus on scientist’s research needs and by following three principle viz; value, service and support.
URL link/website: https://www.acrobiosystems.com/
Royale International are pharmaceutical specialists in handling sensitive temperature-controlled products and deliver with extreme care and precision, all across the globe. The Life Sciences Division manages a wide range of temperature-controlled shipments for the Healthcare and Pharmaceutical industries such as; lifesaving live organs, pre-clinical trials, clinical trials (Phase 1 – 3), blood samples, stem cells, APIs, drug development and commercial medicines. The organisation offers premium logistics solutions via On-Board Couriers & Express freight, and provides quality packaging solutions to clients so that products are safely transported to its destination. All procedures are Customs Authority, Good Distribution Practice (GDP) and International Air Transport Association (IATA) compliant, ensuring shipments arrive at the right place, at the right time and in the required condition.
Pfanstiehl is the market leader of high purity, low endotoxin, low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 103rd anniversary year in 2022. Pfanstiehl is headquartered at Waukegan, IL, USA and has diverse global technical support team across the globe in USA, Europe & APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high characterization, performance, consistency, and quality attributes.
Pfanstiehl’s excipients are critical components in the majority of the global blockbuster biopharmaceutical drugs and vaccines including majority of the Covid -19 vaccines that were administered globally.
For more information about Pfanstiehl Inc, and their products and solutions, please contact us at [email protected] or visit www.Pfanstiehl.com
Eppendorf – Stimulating growth. Cultivating Solutions Efficient bioprocesses are central to the production of biopharmaceuticals, biomass, chemical building blocks, and nutritional products. Scientists from industry and academia trust Eppendorf bioprocess solutions for the cultivation of mammalian, insect, plant, and stem cells, as well as bacteria, yeasts, and fungi. Scalable systems support the upstream bioprocessing cycle from early development to scale-up to pilot-scale production, in working volumes from 65 mL to 2,400 L. Powerful hardware and software tools for process monitoring, control, and analytics, help to build process understanding and facilitate standardized process control. By utilizing the strong synergies between bioreactor technology and polymer manufacturing, Eppendorf developed a wide selection of single-use bioreactors and fermentors which complement its portfolio of glass and stainless-steel vessels. With worldwide technical and application services, clear technical documentation, and preventive maintenance services, Eppendorf ensures reliable system operation. Since 1945, the Eppendorf brand has been synonymous with customer-oriented processes and innovative products, such as laboratory devices and consumables for liquid handling, cell handling and sample handling. Today, Eppendorf and its more than 5000 employees serve as experts and advisors, using their unique knowledge and experience to support laboratories and research institutions around the world.
With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.
PerkinElmer is a leading, global provider of end-to-end solutions that help scientists,
PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.e.
CPC (Colder Products Company) is the leader in single-use connection technology offering a wide variety of cell and gene therapy connection solutions that ensure ease of use and a robust connection. Single-use technologies (SUT) saves time and labor during set-up and between cycles, by eliminating steps, costs of cleaning, sterilization; and eliminating cross-contaminations between batches. CPC connectors have been tested and validated to comply with accepted industry standards; for mechanical strength; extractables and leachables; bacterial ingress and others. Learn more about the MicroCNX™ connectors and our entire portfolio at cpcworldwide.com/cgt to help you connect with confidence.
Limited Super Price - END USER
- Main Conference Access
- Expires 26th May 2023
- Standard Rate SGD 2595
Limited Super Price - VENDOR/BD
- Main Conference Access
- Expires 26th May 2023
- Standard Rate SGD 4395
Asia Pacific Cell & Gene Therapy Excellence Awards 2022
Asia Pacific CGT Excellence Awards 2022 seeks to give recognition to exceptional Cell & Gene Therapy Pioneers, Researchers, Innovators & Manufacturers that facilitate fast advancement in new therapies, R&D and manufacturing. Featuring top Cell & Gene Therapy leaders in the industry, along with the new cell & gene therapy research development, latest advances and technologies and best practices in Cell & Gene manufacturing, the Asia Pacific CGT Excellence Awards 2022 applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.
Poster Presentation - 6th Annual Cell & Gene Therapy World Asia, Singapore
Cell & Gene Therapy growing fast in the Asia region with a lot of support seen from the regulatory and its advancement in research. Many of the Academic & Research Institutes have been contributing to the cell & gene space with great research, discovery & advances. There also have been spin-offs come out of the institutes with promote cell and gene therapy in the region. The Academia plays a crucial role supported by the government and the industry in the growth of the cell and gene space.
At the 6th Annual Cell & Gene Therapy World Asia Summit, we propose to “feature” the top research work done by the Academia - We have had an overwhelming response from some of the key players in the Cell & Gene Manufacturing sector who would be interested in the latest research work done by Academic and Research Institutes to explore the innovations and the way it can be implemented by the industry.
The poster presentation will be viewed by 300+ Cell & Gene industry professionals from top notch Cell & Gene Companies.
Present your expertise to the key cell and gene therapy stakeholders from Asia through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.